These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 26212701)

  • 1. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.
    Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M
    Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system.
    Pietschmann S; von Bueren AO; Kerber MJ; Baumert BG; Kortmann RD; Müller K
    PLoS One; 2015; 10(4):e0121592. PubMed ID: 25860797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
    Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
    Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
    Tanwar MK; Gilbert MR; Holland EC
    Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
    Horbinski C; Wang G; Wiley CA
    Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.
    Ma X; Yoshimoto K; Guan Y; Hata N; Mizoguchi M; Sagata N; Murata H; Kuga D; Amano T; Nakamizo A; Sasaki T
    Neuro Oncol; 2012 Sep; 14(9):1153-62. PubMed ID: 22844109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High CHI3L1 expression is associated with glioma patient survival.
    Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
    Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
    Hegi ME; Janzer RC; Lambiv WL; Gorlia T; Kouwenhoven MC; Hartmann C; von Deimling A; Martinet D; Besuchet Schmutz N; Diserens AC; Hamou MF; Bady P; Weller M; van den Bent MJ; Mason WP; Mirimanoff RO; Stupp R; Mokhtari K; Wesseling P; ;
    Acta Neuropathol; 2012 Jun; 123(6):841-52. PubMed ID: 22249618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
    Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum YKL-40 following resection for cerebral glioblastoma.
    Bernardi D; Padoan A; Ballin A; Sartori M; Manara R; Scienza R; Plebani M; Della Puppa A
    J Neurooncol; 2012 Apr; 107(2):299-305. PubMed ID: 22102082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein and mRNA levels of YKL-40 in high-grade glioma.
    Kazakova MH; Staneva DN; Koev IG; Staikov DG; Mateva N; Timonov PT; Miloshev GA; Sarafian VS
    Folia Biol (Praha); 2014; 60(6):261-7. PubMed ID: 25629266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifocal glioblastoma multiforme in the posterior fossa mimicking cerebral metastases: case presentation and review of the current literature.
    Walter J; Koch A; Herbold C; Schiffler S; Reichart R; Waschke A; Kalff R
    J Neurol Surg A Cent Eur Neurosurg; 2013 Dec; 74 Suppl 1():e30-5. PubMed ID: 23427036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive Therapies for Extraneural Metastases from Glioblastoma, as Confirmed with the OncoScan Assay.
    Xu M; Wang Y; Xu J; Yao Y; Yu WX; Zhong P
    World Neurosurg; 2016 Jun; 90():698.e7-698.e11. PubMed ID: 26852708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
    Berkman RA; Merrill MJ; Reinhold WC; Monacci WT; Saxena A; Clark WC; Robertson JT; Ali IU; Oldfield EH
    J Clin Invest; 1993 Jan; 91(1):153-9. PubMed ID: 8380810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.